68Ga-FAPI PET/CT in Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy
Authors:
- 3 March 2021
- journal article
- editorial
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 46 (5) , 427-430
Abstract
Differentiated thyroid cancer with thyroglobulin elevation and negative iodine scintigraphy (TENIS) syndrome is a diagnostic and therapy dilemma. In this study, we present a case of TENIS with detectable metastases in the larynx and lung on the CT scan. 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT was performed for further detection of tumor recurrence and metastases, which showed intense 68Ga-FAPI activity in the metastatic lesions. To the best of our knowledge, this is the first case of TENIS presenting with FAPI-avid metastatic lesions, demonstrating its usefulness for localizing recurrent or metastatic lesions in patients with TENIS.Keywords
This publication has 8 references indexed in Scilit:
- Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of CancerJournal of Nuclear Medicine, 2019
- Differentiated Thyroid Cancer Outcomes After Surgery and Activity-Adjusted 131I TheragnosticsClinical Nuclear Medicine, 2019
- Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the ClassificationsThyroid®, 2018
- Nuclear Molecular and Theranostic Imaging for Differentiated Thyroid CancerMolecular Imaging and Radionuclide Therapy, 2017
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2016
- Preablation 131-I Scans With SPECT/CT in Postoperative Thyroid Cancer Patients: What Is the Impact on Staging?The Journal of Clinical Endocrinology & Metabolism, 2013
- Progress in molecular-based management of differentiated thyroid cancerThe Lancet, 2013